Translocator Protein (18 kDa): A Promising Therapeutic Target and Diagnostic Tool for Cardiovascular Diseases
Figure 2
Three-dimensional structures of representative TSPO ligands. (a) endogenous ligands, such as protoporphyrin IX, diazepam binding inhibitor (DBI), and phospholipase A2 (PLA2); (b) classical synthetic ligands, such as 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one (Ro5-4864) and PK 11195; (c) novel ligands, such as N,N-di-n-hexyl 2-(4-fluorophenyl)indole-3-acetamide (FGIN-1-27), 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]-indole-1-acetamide (SSR180575) and 3,5-Seco-4-nor-cholestan-5-one oxime-3-ol (TRO40303).
